Neoadjuvant therapy: what are the lessons so far?

摘要: Lessons have recently been learned in the use of neoadjuvant chemotherapy. This article explains how diagnosis a pathologic complete response (pCR) can avoid an unfavorable prognosis patients with high-risk breast cancer; surrogacy pCR for long-term survival remains questionable; translational biomarker studies not helpful identifying high chance treatment benefit; assessment without at risk and which clinical trials will be available these near future; might require less locoregional treatment.